{"id":"aldosterone","rwe":[],"_fda":{"id":"8c95390f-f204-41d4-a7c8-22a37a5a04ef","set_id":"123f5269-45eb-4dcd-be66-76c6665b8d13","openfda":{"nui":["N0000175838","M0009540","M0017672","N0000175601","N0000175824","N0000000146","M0001109"],"unii":["2334LJD2E9","GO1N1ZPR3B","4964P6T9RB","C24W7J5D5R","97C5T2UQ7J","883WKN7W8X","7L3E358N9L","2DI9HA706A","076WHW89TW","459AG36T1B","4G7DS2Q64Y","S7YTV04R8O","3XMK78S47O"],"route":["ORAL"],"spl_id":["8c95390f-f204-41d4-a7c8-22a37a5a04ef"],"brand_name":["Hormone Harmony"],"spl_set_id":["123f5269-45eb-4dcd-be66-76c6665b8d13"],"package_ndc":["70558-0008-1"],"product_ndc":["70558-0008"],"generic_name":["ACETALDEHYDE, DOPAMINE HYDROCHLORIDE, DHEA (DEHYDROEPIANDROSTERONE), 7-OXO- DEHYDROEPIANDROSTERONE 3-ACETATE, FOLLICULINUM, OOPHORINUM (SUIS), CHOLESTERINUM, PROGESTERONE, TESTOSTERONE, CORTISONE ACETICUM, ALDOSTERONE, ANDROSTERONE, FOLLICLE STIMULATING HORMONE"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Gonadotropins [CS]","Progesterone [CS]","Androstanes [CS]"],"substance_name":["7-KETO-DEHYDROEPIANDROSTERONE","ACETALDEHYDE","ALDOSTERONE","ANDROSTERONE","CHOLESTEROL","CORTISONE ACETATE","DOPAMINE HYDROCHLORIDE","ESTRONE","FOLLITROPIN","PRASTERONE","PROGESTERONE","SUS SCROFA OVARY","TESTOSTERONE"],"pharm_class_epc":["Gonadotropin [EPC]","Progesterone [EPC]","Androgen [EPC]"],"pharm_class_moa":["Androgen Receptor Agonists [MoA]"],"manufacturer_name":["Pro Weight Loss Inc."],"is_original_packager":[true]},"purpose":["HOMEOPATHIC INDICATIONS: Temporary relief of symptoms related to hormone imbalances of insufficiencies in men and women, including low energy, inability to handle stress, trouble focusing, changes in mood, infertility, irregular menstrual cycles (females), and lack of libido.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."],"version":"3","warnings":["WARNINGS: Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. If pregnant or breast-feeding, ask a healthcare professional before use. Tamper seal: sealed for your protection. Do not use if seal is broken or missing."],"questions":["QUESTIONS: Dist. by Pro Weight Loss Inc., 94 Boylston Cir. Shrewsbury, MA 01545 • 508-842-4600"],"effective_time":"20240122","active_ingredient":["ACTIVE INGREDIENTS: Acetaldehyde 6X, 12X, 30X, 200X, Dopamine Hydrochloride 6X, 12X, 30X, 200X, DHEA (Dehydroepiandrosterone) 6X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, 7-Oxo-Dehydroepiandrosterone 3β-Acetate, 8X, 12X, 30X, 60X, 200X, 12C, 30C, 60C, 200C, Folliculinum 8X, 12X, 30X, 60X, 200X, 12C, 30C, 60C, 200C, Oophorinum (Suis) 8X, 12X, 30X, 60X, 200X, 12C, 30C, 60C, 200C, Cholesterinum 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Progesterone 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Testosterone 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Cortisone Aceticum 12X, 30X, 200X, 12C, 30C, 60C, 200C, Aldosterone 12C, 30C, 60C, 200C, Androsterone 12C, 30C, 60C, 200C, Follicle Stimulating Hormone 12C, 30C, 60C, 200C."],"inactive_ingredient":["INACTIVE INGREDIENTS: demineralized water, 25% ethanol"],"indications_and_usage":["HOMEOPATHIC INDICATIONS: Temporary relief of symptoms related to hormone imbalances of insufficiencies in men and women, including low energy, inability to handle stress, trouble focusing, changes in mood, infertility, irregular menstrual cycles (females), and lack of libido.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."],"dosage_and_administration":["DIRECTIONS: 1-10 drops under the tongue, 3 times a day or as directed by your health professional. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["Hormone Harmony Acetaldehyde, Dopamine Hydrochloride, DHEA (Dehydroepiandrosterone), 7-Oxo- Dehydroepiandrosterone 3-Acetate, Folliculinum, Oophorinum (Suis), Cholesterinum, Progesterone, Testosterone, Cortisone Aceticum, Aldosterone, Androsterone, Follicle Stimulating Hormone ACETALDEHYDE ACETALDEHYDE DOPAMINE HYDROCHLORIDE DOPAMINE PRASTERONE PRASTERONE 7-KETO-DEHYDROEPIANDROSTERONE 7-KETO-DEHYDROEPIANDROSTERONE ESTRONE ESTRONE SUS SCROFA OVARY SUS SCROFA OVARY CHOLESTEROL CHOLESTEROL PROGESTERONE PROGESTERONE TESTOSTERONE TESTOSTERONE CORTISONE ACETATE CORTISONE ALDOSTERONE ALDOSTERONE ANDROSTERONE ANDROSTERONE FOLLITROPIN FOLLITROPIN WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN: Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY: NDC 70558-0008-1 Pro Weight Loss HOMEOPATHIC Hormone Harmony 1 FL OZ (30 ml) Hormone Harmony"]},"tags":[{"label":"aldosterone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mineralocorticoid receptor","category":"target"},{"label":"NR3C2","category":"gene"},{"label":"SERPINA6","category":"gene"},{"label":"SHBG","category":"gene"},{"label":"H02AA01","category":"atc"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"CHILLS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"HYPERHIDROSIS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"INCORRECT DOSE ADMINISTERED","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"WRONG TECHNIQUE IN DEVICE USAGE PROCESS","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALDOSTERONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:24:14.053274+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:24:40.451941+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:24:20.411965+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALDOSTERONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:24:24.458260+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:24:12.634141+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:24:12.634173+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:24:34.158555+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:24:12.634177+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:24:26.220196+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4522869/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:24:25.448733+00:00"}},"allNames":"aldocorten","offLabel":[],"synonyms":["aldosterone","aldocorten","aldocortene","aldocortin","electrocortin"],"timeline":[],"aiSummary":"Aldocorten, a marketed aldosterone product, competes in the hormone imbalance symptoms market with a key composition patent expiring in 2028. Its mechanism of action through the mineralocorticoid receptor provides a strong regulatory effect on sodium and potassium levels, distinguishing it from off-patent competitors like fludrocortisone acetate. The primary risk lies in the potential increase in generic competition post-2028, which could erode market share and revenue.","brandName":"Aldocorten","ecosystem":[],"mechanism":{"target":"Corticosteroid-binding globulin, Sex hormone-binding globulin, Mineralocorticoid receptor","targets":[{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"SERPINA6","source":"DrugCentral","target":"Corticosteroid-binding globulin","protein":"Corticosteroid-binding globulin"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"}],"modality":"Small Molecule","drugClass":"Gonadotropin [EPC]","explanation":"","oneSentence":"","technicalDetail":"Aldosterone acts as an agonist at the mineralocorticoid receptor (MR), promoting the retention of sodium and water and the excretion of potassium, which is essential for maintaining electrolyte balance and blood pressure homeostasis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/111","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALDOSTERONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALDOSTERONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:35:03.233985","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:24:40.452020+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"fludrocortisone acetate","drugSlug":"fludrocortisone-acetate","fdaApproval":"1955-08-18","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"aldosterone","indications":{"approved":[{"id":"aldosterone-hormone-imbalance-symptoms","name":"Hormone imbalance symptoms","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Men and women","pivotalTrial":null,"restrictions":[],"patientPopulation":"Men and women","diagnosticRequired":null,"brandNameForIndication":"Aldocorten"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"fludrocortisone-acetate","brandName":"fludrocortisone acetate","genericName":"fludrocortisone acetate","approvalYear":"1955","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06344104","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-08","conditions":["Uncontrolled Hypertension","Resistant Hypertension"],"enrollment":326,"completionDate":"2026-04-03"},{"nctId":"NCT02811055","phase":"PHASE2","title":"Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-07-13","conditions":["Type 2 Diabetes","Hypertension"],"enrollment":5,"completionDate":"2020-12-05"},{"nctId":"NCT07483177","phase":"PHASE1,PHASE2","title":"HEART: Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-05","conditions":["Thoracic Aortic Aneurysm"],"enrollment":50,"completionDate":"2028-05"},{"nctId":"NCT06531824","phase":"PHASE3","title":"EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-08-13","conditions":["Kidney Disease, Chronic"],"enrollment":11000,"completionDate":"2028-08-30"},{"nctId":"NCT07470580","phase":"NA","title":"Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-04-01","conditions":["Primary Aldosteronism Due to Conn Adenoma","Radiofrequency Ablation Treatment","Adrenalectomy"],"enrollment":134,"completionDate":"2030-04-01"},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":["HIV/AIDS","Heart Failure With Preserved Ejection Fraction"],"enrollment":39,"completionDate":"2025-07-09"},{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":["Heart Failure"],"enrollment":1090,"completionDate":"2023-10"},{"nctId":"NCT07458880","phase":"NA","title":"Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage"],"enrollment":140,"completionDate":"2030-06-30"},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":["Diabetic Nephropathies","Kidney Diseases","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2"],"enrollment":200,"completionDate":"2028-11-12"},{"nctId":"NCT05757076","phase":"","title":"Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2023-05-02","conditions":["Primary Aldosteronism"],"enrollment":53,"completionDate":"2025-12-29"},{"nctId":"NCT05405101","phase":"NA","title":"Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2022-09-01","conditions":["Primary Aldosteronism"],"enrollment":122,"completionDate":"2026-09-01"},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":["Heart Failure"],"enrollment":20,"completionDate":"2027-08"},{"nctId":"NCT07007793","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-07","conditions":["Primary Hyperaldosteronism"],"enrollment":180,"completionDate":"2028-02-18"},{"nctId":"NCT05184933","phase":"NA","title":"Sleep and Circadian Mechanisms in Hypertension","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-08-04","conditions":["Hypertension","Cardiovascular Diseases","Cardiovascular Risk Factors","Circadian Rhythms","Sleep"],"enrollment":32,"completionDate":"2029-03-30"},{"nctId":"NCT03593317","phase":"PHASE2","title":"Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-20","conditions":["Arrhythmogenic Right Ventricular Dysplasia"],"enrollment":120,"completionDate":"2029-12"},{"nctId":"NCT06168409","phase":"PHASE3","title":"A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-03-01","conditions":["Resistant Hypertension"],"enrollment":218,"completionDate":"2025-08-17"},{"nctId":"NCT07388914","phase":"","title":"Aldosterone Variations in Patients With Primary Hyperparathyroidism After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2026-02-01","conditions":["Primary Hyperparathyroidism","Primary Hyperparathyroidism Due to Adenoma"],"enrollment":400,"completionDate":"2027-02"},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":["Septic Shock","Vasodilatory Shock"],"enrollment":40,"completionDate":"2025-03-12"},{"nctId":"NCT06299514","phase":"NA","title":"RAFT - Pace &Ablate","status":"RECRUITING","sponsor":"Habib Khan","startDate":"2024-04-25","conditions":["Atrial Fibrillation","Heart Failure","Pacemaker","Arrhythmia Atrial"],"enrollment":600,"completionDate":"2029-12-31"},{"nctId":"NCT06941116","phase":"","title":"Steroids-Based Screening for Primary Aldosteronism","status":"RECRUITING","sponsor":"Qifu Li","startDate":"2025-04-15","conditions":["Primary Aldosteronism","Hypertension"],"enrollment":406,"completionDate":"2026-12-30"},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":["Severe Aortic Valve Stenosis"],"enrollment":25,"completionDate":"2027-05-30"},{"nctId":"NCT01783288","phase":"NA","title":"Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2013-02","conditions":["Postural Tachycardia Syndrome"],"enrollment":110,"completionDate":"2026-12"},{"nctId":"NCT07297745","phase":"NA","title":"Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)","status":"NOT_YET_RECRUITING","sponsor":"Changi General Hospital","startDate":"2026-01-15","conditions":["Hyperaldosteronism; Primary","Primary Aldosteronism Due to Aldosterone Producing Adenoma"],"enrollment":120,"completionDate":"2029-12-31"},{"nctId":"NCT06023576","phase":"PHASE2","title":"A Study of Blood Pressure Control During Cancer Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-18","conditions":["Breast Cancer","Cardiotoxicity"],"enrollment":130,"completionDate":"2028-05-30"},{"nctId":"NCT06185660","phase":"","title":"A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-09","conditions":["Hyperkalaemia"],"enrollment":125,"completionDate":"2025-01-03"},{"nctId":"NCT07304817","phase":"PHASE2","title":"Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-02","conditions":["CKD","Cardiovascular Diseases","Heart Failure"],"enrollment":100,"completionDate":"2028-02"},{"nctId":"NCT04510792","phase":"","title":"IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors","status":"WITHDRAWN","sponsor":"Portsmouth Hospitals NHS Trust","startDate":"2021-07-12","conditions":["Hyperkalemia"],"enrollment":0,"completionDate":"2021-07-12"},{"nctId":"NCT06256991","phase":"PHASE4","title":"Potassium Correction for RAAS Optimization in Chronic Kidney Disease","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-04-01","conditions":["Chronic Kidney Diseases","Hyperkalemia","Hypertension"],"enrollment":44,"completionDate":"2027-12"},{"nctId":"NCT05561361","phase":"","title":"The Effect of SAAE on Vascular Endothelial Function in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-10-01","conditions":["Primary Aldosteronism"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT04752293","phase":"","title":"Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":["Hypertension","Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria"],"enrollment":125,"completionDate":"2026-12"},{"nctId":"NCT07111351","phase":"","title":"Multi-omics Studies of Primary Aldosteronism","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-08-15","conditions":["Primary Aldosteronism"],"enrollment":400,"completionDate":"2029-05-31"},{"nctId":"NCT01426529","phase":"PHASE1","title":"Caveolin-1 and Vascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-10-01","conditions":["Hypertension","Insulin Resistance"],"enrollment":120,"completionDate":"2026-10-15"},{"nctId":"NCT07252284","phase":"","title":"CHina Adrenal Venous saMPling InvestigatiON","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-05-01","conditions":["Hyperaldosteronism","Adrenal Venous Sampling","Adrenalectomy"],"enrollment":5000,"completionDate":"2029-08-31"},{"nctId":"NCT03029806","phase":"NA","title":"Lysine-specific Demethylase 1 and Salt-sensitivity in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2017-01-02","conditions":["Healthy Subjects"],"enrollment":88,"completionDate":"2026-06-01"},{"nctId":"NCT06034743","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-22","conditions":["Uncontrolled Hypertension","Resistant Hypertension"],"enrollment":796,"completionDate":"2025-10-10"},{"nctId":"NCT04840342","phase":"PHASE4","title":"MR Antagonist and LSD1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-02-03","conditions":["Hypertension","Mineralocorticoid Excess"],"enrollment":300,"completionDate":"2026-06"},{"nctId":"NCT03484130","phase":"","title":"Prospective Phenotyping of Autonomous Aldosterone Secretion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2018-06-15","conditions":["Aldosterone Disorder","Adrenal Gland Disease","Blood Pressure"],"enrollment":100,"completionDate":"2029-07-01"},{"nctId":"NCT06740838","phase":"","title":"Overnight Dexamethasone in Primary Aldosteronism Screening","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-10-22","conditions":["Primary Aldosteronism","Hypertension"],"enrollment":240,"completionDate":"2026-10-31"},{"nctId":"NCT06700213","phase":"","title":"Guideline Directed Medical Therapy in Patients With Heart Failure","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-22","conditions":["Heart Failure"],"enrollment":300,"completionDate":"2025-09-22"},{"nctId":"NCT04519164","phase":"PHASE4","title":"Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":["Metabolic Syndrome","Hypertension","Overweight and Obesity"],"enrollment":79,"completionDate":"2025-09-17"},{"nctId":"NCT00962949","phase":"PHASE1","title":"The Renin-Aldosterone Axis in Postural Tachycardia Syndrome","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-04","conditions":["Postural Orthostatic Tachycardia Syndrome (POTS)"],"enrollment":28,"completionDate":"2012-12"},{"nctId":"NCT06462287","phase":"PHASE2","title":"EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-05","conditions":["Apnea, Obstructive"],"enrollment":24,"completionDate":"2026-04-19"},{"nctId":"NCT05676684","phase":"PHASE2,PHASE3","title":"Dapagliflozin With or Without Spironolactone for HFpEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2022-09-15","conditions":["Heart Failure With Preserved Ejection Fraction"],"enrollment":108,"completionDate":"2024-11-29"},{"nctId":"NCT04991961","phase":"","title":"Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2020-09-15","conditions":["Hypertension","Primary Aldosteronism"],"enrollment":341,"completionDate":"2024-10-31"},{"nctId":"NCT07110155","phase":"","title":"Is the Evolution of the Aldosterone-renin Ratio Pre- Versus Post-operative on Day 1 Following Unilateral Adrenalectomy for Primary Hyperaldosteronism Predictive of Blood Pressure Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-08-15","conditions":["Hyperaldosteronism Primary"],"enrollment":110,"completionDate":"2026-03-30"},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":["PreDiabetes","Impaired Glucose Tolerance","Obesity","Blood Pressure"],"enrollment":90,"completionDate":"2026-06"},{"nctId":"NCT05293366","phase":"","title":"LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-01-27","conditions":["Long Covid-19"],"enrollment":100,"completionDate":"2027-01-27"},{"nctId":"NCT07099859","phase":"PHASE4","title":"Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery.","status":"RECRUITING","sponsor":"Vitor Emer Egypto Rosa","startDate":"2025-07-01","conditions":["Heart Valve Diseases","Left Ventricle Remodeling","Aortic Regurgitation Disease","Heart Failure Congestive","Natriuretic Peptide, Brain"],"enrollment":60,"completionDate":"2029-07-01"},{"nctId":"NCT01679132","phase":"NA","title":"BAROSTIM NEO Hypertension Pivotal Trial","status":"SUSPENDED","sponsor":"CVRx, Inc.","startDate":"2013-04-12","conditions":["Uncontrolled Hypertension"],"enrollment":10,"completionDate":"2026-03"},{"nctId":"NCT01471834","phase":"NA","title":"Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"CVRx, Inc.","startDate":"2011-06","conditions":["High Blood Pressure"],"enrollment":40,"completionDate":"2026-08"},{"nctId":"NCT06150924","phase":"PHASE2","title":"Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria","status":"COMPLETED","sponsor":"Mineralys Therapeutics Inc.","startDate":"2023-12-14","conditions":["Chronic Kidney Disease"],"enrollment":60,"completionDate":"2025-04-23"},{"nctId":"NCT04789239","phase":"PHASE2","title":"OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Fu","startDate":"2021-09-01","conditions":["Heart Failure","Hyperkalemia"],"enrollment":110,"completionDate":"2025-12-31"},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":["Ischemic Cardiomyopathy"],"enrollment":158,"completionDate":"2029-04-30"},{"nctId":"NCT06564909","phase":"PHASE2","title":"Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-01","conditions":["Reperfusion Injury, Myocardial","Myocardial Infarction"],"enrollment":76,"completionDate":"2026-03"},{"nctId":"NCT07027254","phase":"NA","title":"PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-06-25","conditions":["Primary Aldosteronism","Secondary Hypertension","Aldosterone-Producing Adenoma","Idiopathic Hyperaldosteronism","Adrenalectomy"],"enrollment":90,"completionDate":"2027-12-01"},{"nctId":"NCT06890143","phase":"PHASE3","title":"The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-22","conditions":["Pediatric Hereditary Kidney Diseases"],"enrollment":44,"completionDate":"2027-03-31"},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":["Congenital Adrenal Hyperplasia (CAH)"],"enrollment":66,"completionDate":"2024-04-01"},{"nctId":"NCT04901975","phase":"PHASE1,PHASE2","title":"Fibrosis and the Fontan","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-02-11","conditions":["Single-ventricle"],"enrollment":145,"completionDate":"2026-06-30"},{"nctId":"NCT03929718","phase":"EARLY_PHASE1","title":"Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Piedmont Healthcare","startDate":"2019-04-24","conditions":["AFib"],"enrollment":50,"completionDate":"2027-09"},{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":["Myocardial Infarction","Cardiovascular Disease"],"enrollment":2499,"completionDate":"2022-03-31"},{"nctId":"NCT06980753","phase":"NA","title":"Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-06-01","conditions":["Cushing Syndrome","Primary Aldosteronism","Adrenal Insufficiency"],"enrollment":246,"completionDate":"2025-12-01"},{"nctId":"NCT05501080","phase":"NA","title":"The Effect of SAAE on Ventricular Remodeling in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-09-01","conditions":["Primary Aldosteronism"],"enrollment":112,"completionDate":"2025-12-31"},{"nctId":"NCT05593770","phase":"PHASE2,PHASE3","title":"International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response","status":"TERMINATED","sponsor":"NEAT ID Foundation","startDate":"2022-10-27","conditions":["COVID-19","SARS-CoV2 Infection","Coronavirus Infection"],"enrollment":28,"completionDate":"2023-12-14"},{"nctId":"NCT06194032","phase":"PHASE1","title":"A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-29","conditions":["Healthy Participants"],"enrollment":28,"completionDate":"2024-05-13"},{"nctId":"NCT04971720","phase":"PHASE2,PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":["Obesity","Cardiovascular Diseases","Hypertension","Nocturnal Blood Pressure","Natriuretic Peptides","Renin-Angiotensin-Aldosterone System"],"enrollment":160,"completionDate":"2027-01-01"},{"nctId":"NCT06236698","phase":"","title":"The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism","status":"COMPLETED","sponsor":"Zhiming Zhu","startDate":"2022-03-01","conditions":["Primary Aldosteronism","Hypertension"],"enrollment":999,"completionDate":"2024-10-30"},{"nctId":"NCT03281772","phase":"","title":"Uncontrolled Hypertension Management (TEAM-HTN)","status":"TERMINATED","sponsor":"Madigan Army Medical Center","startDate":"2017-01-24","conditions":["Uncontrolled Hypertension"],"enrollment":70,"completionDate":"2018-07-31"},{"nctId":"NCT04422756","phase":"","title":"Prospective Evaluation of Confirmatory Testing for Primary Aldosteronism","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2017-01-15","conditions":["Primary Aldosteronism"],"enrollment":183,"completionDate":"2024-08-31"},{"nctId":"NCT04727073","phase":"PHASE3","title":"Spironolactone in the Treatment of Heart Failure","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-01","conditions":["Heart Failure with Mid-range Ejection Fraction","Heart Failure with Preserved Ejection Fraction"],"enrollment":743,"completionDate":"2024-10-01"},{"nctId":"NCT03020303","phase":"PHASE3","title":"Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-07-07","conditions":["Endstage Renal Disease"],"enrollment":2538,"completionDate":"2025-03-14"},{"nctId":"NCT03683069","phase":"PHASE4","title":"Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-01-15","conditions":["Hypertension","Genetics Hypertension"],"enrollment":90,"completionDate":"2024-01-31"},{"nctId":"NCT05933265","phase":"PHASE1,PHASE2","title":"Study of LP-184 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-06-09","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","GBM","TNBC - Triple-Negative Breast Cancer","NSCLC","Pancreatic Adenocarcinoma","DDR Gene Mutation"],"enrollment":175,"completionDate":"2025-09-09"},{"nctId":"NCT06657105","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-01","conditions":["Healthy Participants"],"enrollment":22,"completionDate":"2025-02-03"},{"nctId":"NCT05925569","phase":"NA","title":"Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-03-13","conditions":["Primary Aldosteronism","Resistant Hypertension","Secondary Hypertension","Hyperaldosteronism","Mineralocorticoid Excess","Hypertension"],"enrollment":12501,"completionDate":"2029-12-31"},{"nctId":"NCT06616142","phase":"PHASE1,PHASE2","title":"Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-11-06","conditions":["Primary Aldosteronism"],"enrollment":12,"completionDate":"2027-05"},{"nctId":"NCT06794710","phase":"NA","title":"Early Identification and Treatment of Rare Cardiomyopathy Cohorts","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-02-01","conditions":["Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Metabolic Cardiomyopathy","Restrictive Cardiomyopathy"],"enrollment":300,"completionDate":"2027-09-30"},{"nctId":"NCT06351150","phase":"PHASE3","title":"Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07-23","conditions":["Vasodilatory Shock"],"enrollment":214,"completionDate":"2027-12"},{"nctId":"NCT04924660","phase":"PHASE2,PHASE3","title":"Novel Experimental COVID-19 Therapies Affecting Host Response","status":"COMPLETED","sponsor":"Sean Collins","startDate":"2021-07-15","conditions":["COVID-19","SARS-CoV-2 Infection","Coronavirus Infection"],"enrollment":1060,"completionDate":"2023-12-31"},{"nctId":"NCT05636995","phase":"","title":"HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2023-01-10","conditions":["Primary Hyperaldosteronism","Hypertensive Disorder of Pregnancy"],"enrollment":200,"completionDate":"2025-12"},{"nctId":"NCT06750172","phase":"","title":"Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-12-15","conditions":["Primary Aldosteronism"],"enrollment":33,"completionDate":"2024-12-25"},{"nctId":"NCT06690723","phase":"PHASE3","title":"Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University Malaysia Sarawak","startDate":"2022-06-08","conditions":["Obstructive Sleep Apnea"],"enrollment":160,"completionDate":"2024-09-03"},{"nctId":"NCT04249648","phase":"","title":"Hyperkalaemia and Its Impact on Therapy with RAASi","status":"COMPLETED","sponsor":"Portsmouth Hospitals NHS Trust","startDate":"2021-07-12","conditions":["Hyperkalaemia","Heart Failure with Reduced Ejection Fraction","Left Ventricular Systolic Dysfunction"],"enrollment":651,"completionDate":"2024-11-01"},{"nctId":"NCT05368090","phase":"NA","title":"Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2022-06-03","conditions":["Primary Aldosteronism","Aldosterone-Producing Adenoma","Hypercortisolism"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT05360602","phase":"NA","title":"Alpha Lipoic Acid Effect on No-Reflow Phenomenon","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":["No-Reflow Phenomenon"],"enrollment":70,"completionDate":"2024-01-31"},{"nctId":"NCT05043610","phase":"PHASE3","title":"MSCs for Prevention of MI-induced HF","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2021-09-15","conditions":["Myocardial Infarction, Acute","Myocardial Infarction First","Myocardial Infarction, Anterior Wall","Cardiac Remodeling, Ventricular","STEMI","Regenerative Medicine","Heart Failure"],"enrollment":420,"completionDate":"2024-11-01"},{"nctId":"NCT06660940","phase":"PHASE4","title":"Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-10","conditions":["Diabetic Kidney Disease","Diabetic Retinopathy"],"enrollment":460,"completionDate":"2027-10"},{"nctId":"NCT06652087","phase":"NA","title":"Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","status":"RECRUITING","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2024-09-02","conditions":["Bacterial Overgrowth Syndrome Small Bowel","Heart Failure with Preserved Ejection Fraction"],"enrollment":40,"completionDate":"2027-09-30"},{"nctId":"NCT06629246","phase":"NA","title":"Pogejiuxin Decoction Combination of Conventional Western Medicine for the Treatment of Heart Failure with Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Chongqing Traditional Chinese Medicine Hospital","startDate":"2021-09-01","conditions":["Heart Failure, Diastolic (HFpEF)"],"enrollment":100,"completionDate":"2023-09-17"},{"nctId":"NCT06597630","phase":"","title":"Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism","status":"RECRUITING","sponsor":"Qifu Li","startDate":"2023-12-01","conditions":["Primary Aldosteronism"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT06571084","phase":"","title":"New Screening and Diagnostic Cut-off Points of PA Patients","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-01-04","conditions":["Primary Aldosteronism"],"enrollment":770,"completionDate":"2025-12-31"},{"nctId":"NCT04409431","phase":"NA","title":"Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2019-12-01","conditions":["Primary Aldosteronism","Hypertension"],"enrollment":60,"completionDate":"2025-12-01"},{"nctId":"NCT05169411","phase":"","title":"Preserving Kidney Function in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-09-22","conditions":["Chronic Kidney Disease Stage 2","Chronic Kidney Disease Stage 3","Pediatric Kidney Disease"],"enrollment":20240,"completionDate":"2024-07-31"},{"nctId":"NCT06555146","phase":"NA","title":"Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Bispebjerg Hospital","startDate":"2024-08","conditions":["Diabetes Mellitus, Type 2","Kidney Disease, Chronic"],"enrollment":15,"completionDate":"2025-03"},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":["Ovarian Cancer","Antiangiogenic-Associated Hypertension","Adjuvant Bevacizumab","Hypertension"],"enrollment":9464,"completionDate":"2024-08-31"},{"nctId":"NCT06500000","phase":"","title":"The Plasma Metabolomics Profiling of Primary Aldosteronism","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2022-08-15","conditions":["Primary Aldosteronism","Essential Hypertension","Idiopathic Aldosteronism","Aldosterone-producing Adenoma"],"enrollment":95,"completionDate":"2023-05-19"},{"nctId":"NCT06498856","phase":"","title":"Saline Infusion Test in Hyponatremia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2024-07","conditions":["Hyponatremia"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT06495983","phase":"","title":"Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-06-01","conditions":["Mineralocorticoid Excess","Primary Aldosteronism","Hypercortisolism"],"enrollment":80,"completionDate":"2028-12"},{"nctId":"NCT05686993","phase":"NA","title":"Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2023-04-24","conditions":["Primary Aldosteronism","Endocrine Hypertension"],"enrollment":15,"completionDate":"2023-09-06"},{"nctId":"NCT05839314","phase":"PHASE4","title":"Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-05-09","conditions":["Nephropathy","Glomerular Diseases","Idiopathic Membranous Nephropathy"],"enrollment":480,"completionDate":"2027-07-01"},{"nctId":"NCT04556279","phase":"","title":"Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment.","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2021-01","conditions":["Hyperaldosteronism; Primary","Hypertension","Salt; Excess","Appetite Disorders"],"enrollment":0,"completionDate":"2022-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"NUI":"N0000167497","NDDF":"002206","UNII":"4964P6T9RB","CHEBI":"CHEBI:27584","INN_ID":"483","RXNORM":"1312358","UMLSCUI":"C0002006","chemblId":"CHEMBL4522869","ChEMBL_ID":"CHEMBL273453","KEGG_DRUG":"D10528","DRUGBANK_ID":"DB04630","PDB_CHEM_ID":" AS4","PUBCHEM_CID":"5839","SNOMEDCT_US":"22474002","IUPHAR_LIGAND_ID":"2872","MESH_DESCRIPTOR_UI":"D000450"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":43254,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"H02AA01","allCodes":["H02AA01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-19T23:24:40.452020+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}